← Back to Search

Behavioral Intervention

Motivational enhancement therapy for Breast Cancer (MI for AIs Trial)

Phase 2 & 3

Waitlist Available

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

English-speaking women, prescribed their first aromatase inhibitor medication. Been identified as non-adherent following a 6-month observation run-in period (Phase 1).

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12-months

Awards & highlights

MI for AIs Trial Summary

This trial will test whether motivational interviewing can improve adherence to aromatase inhibitors in a community sample of patients.

Eligible Conditions

Breast Cancer
Medication Adherence

MI for AIs Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

MI for AIs Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Medication adherence measured using medication possession ratio (MPR)

Secondary outcome measures

Motivation for medication adherence

Self-report medication adherence

Other outcome measures

Self Efficacy for Medication Adherence

Side effects data

From 2008 Phase 2 trial • 38 Patients • NCT00360269

47%

Gastrointestinal

37%

Headache

37%

Sinus/allergies/flu-like symptoms

32%

Dizziness/lightheaded

32%

Musculoskeletal

26%

Sexual dysfunction

26%

Other

16%

Hot/cold flashes

16%

Dry mouth

16%

Drowsiness

16%

Anxiety/depression

11%

Irritability

100%

80%

60%

40%

20%

Study treatment Arm

Atomoxetine

Placebo

MI for AIs Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: TreatmentExperimental Treatment1 Intervention

Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.

Group II: ControlPlacebo Group1 Intervention

Attend 4 in-person sessions to complete questionnaires and receive educational handouts.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Motivational enhancement therapy

2008

Completed Phase 2

~730

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor

791 Previous Clinical Trials

868,606 Total Patients Enrolled

5 Trials studying Breast Cancer

2,104 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients being actively sought for this experiment?

"The clinical trial indicated on clinicaltrials.gov is not actively recruiting patients at this time. The trial was initially posted on 2020-10-01 and was last updated on 2019-05-24. There are currently 1510 other clinical trials seeking patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors

Tavis S. Campbell 2020. "Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02883361.